Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10278)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
CGAS
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
Responsed Drug | Niraparib | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
HT29 cells | Colon cancer | Mus musculus | CVCL_A8EZ | |
CT26 cells | Colon adenocarcinoma | Mus musculus | CVCL_7254 | ||
MC-38 cells | Colon adenocarcinoma | Homo sapiens | CVCL_B288 | ||
In Vivo Model |
Six-week-old male BALB/c athymic nude mice were purchased from the Experimental Animal Center of Peking (Beijing, China). Stable cells (5 x 106) were seeded into the right flanks of the mice. After the xenografts had grown to 200 mm3, saline as a vehicle or sorafenib (30 mg/kg) was administered by gavage every day, and the mice were euthanized by the cervical dislocation method five weeks later. Before sacrifice, the tumor sizes and body weights were measured twice per week. The tumor volume (V) was calculated as follows: (L x W2)/2 (length, L, and width, W). The xenografts were excised and further assessed.
Click to Show/Hide
|
||||
Response regulation | Niraparib, a widely used PARPi, augmented cGAS-mediated ferroptosis and immune activation. In colorectal cancer models, cGAS signaling exerts tumor control via ATF3SLC7A11GPX4-mediated ferroptosis and IFNCD8 T cell-mediated antitumor immune response. | ||||
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | |||
Responsed Drug | Zalcitabine | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
Capan-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0026 | ||
In Vivo Model |
NOD SCID mice (394) were purchased from Charles River Laboratories. Indicated wild-type or gene knockdown PANC1 cells (5 x 106 cells) were subcutaneously injected into the dorsal side of NOD SCID mice. At day 7, these mice were administrated with the indicated drug (zalcitabine [50 mg/kg, per day by i.p.], H-151 [750 nM per mouse, once every other day by i.p.], chloroquine [50 mg/kg, once every other day by i.p.], or liproxstatin-1 [10 mg/kg, once every other day by i.p.]) for 2 weeks.
Click to Show/Hide
|
||||
Response regulation | The antiviral drug zalcitabine can suppress pancreatic cancer cell growth through the induction of autophagy-dependent ferroptotic deathin vitroandin vivo. Mechanistically, these effects are dependent on mtDNA stress-induced activation of the CGAS-STING1 pathway. | ||||
Colorectal cancer [ICD-11: 2B91]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Cyclic GMP-AMP synthase (CGAS) | Protein coding | |||
Responsed Drug | Niraparib | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
HT29 cells | Colon cancer | Mus musculus | CVCL_A8EZ | |
CT26 cells | Colon adenocarcinoma | Mus musculus | CVCL_7254 | ||
MC-38 cells | Colon adenocarcinoma | Homo sapiens | CVCL_B288 | ||
In Vivo Model |
Six-week-old male BALB/c athymic nude mice were purchased from the Experimental Animal Center of Peking (Beijing, China). Stable cells (5 x 106) were seeded into the right flanks of the mice. After the xenografts had grown to 200 mm3, saline as a vehicle or sorafenib (30 mg/kg) was administered by gavage every day, and the mice were euthanized by the cervical dislocation method five weeks later. Before sacrifice, the tumor sizes and body weights were measured twice per week. The tumor volume (V) was calculated as follows: (L x W2)/2 (length, L, and width, W). The xenografts were excised and further assessed.
Click to Show/Hide
|
||||
Response regulation | Niraparib, a widely used PARPi, augmented cGAS-mediated ferroptosis and immune activation. In colorectal cancer models, cGAS signaling exerts tumor control via ATF3SLC7A11GPX4-mediated ferroptosis and IFNCD8 T cell-mediated antitumor immune response. | ||||
Pancreatic cancer [ICD-11: 2C10]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | Cyclic GMP-AMP synthase (CGAS) | Protein coding | |||
Responsed Drug | Zalcitabine | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
Capan-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0026 | ||
In Vivo Model |
NOD SCID mice (394) were purchased from Charles River Laboratories. Indicated wild-type or gene knockdown PANC1 cells (5 x 106 cells) were subcutaneously injected into the dorsal side of NOD SCID mice. At day 7, these mice were administrated with the indicated drug (zalcitabine [50 mg/kg, per day by i.p.], H-151 [750 nM per mouse, once every other day by i.p.], chloroquine [50 mg/kg, once every other day by i.p.], or liproxstatin-1 [10 mg/kg, once every other day by i.p.]) for 2 weeks.
Click to Show/Hide
|
||||
Response regulation | The antiviral drug zalcitabine can suppress pancreatic cancer cell growth through the induction of autophagy-dependent ferroptotic deathin vitroandin vivo. Mechanistically, these effects are dependent on mtDNA stress-induced activation of the CGAS-STING1 pathway. | ||||
Niraparib
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Cystine/glutamate transporter (SLC7A11) | Driver; Suppressor | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
HT29 cells | Colon cancer | Mus musculus | CVCL_A8EZ | |
CT26 cells | Colon adenocarcinoma | Mus musculus | CVCL_7254 | ||
MC-38 cells | Colon adenocarcinoma | Homo sapiens | CVCL_B288 | ||
In Vivo Model |
Six-week-old male BALB/c athymic nude mice were purchased from the Experimental Animal Center of Peking (Beijing, China). Stable cells (5 x 106) were seeded into the right flanks of the mice. After the xenografts had grown to 200 mm3, saline as a vehicle or sorafenib (30 mg/kg) was administered by gavage every day, and the mice were euthanized by the cervical dislocation method five weeks later. Before sacrifice, the tumor sizes and body weights were measured twice per week. The tumor volume (V) was calculated as follows: (L x W2)/2 (length, L, and width, W). The xenografts were excised and further assessed.
Click to Show/Hide
|
||||
Response regulation | Niraparib, a widely used PARPi, augmented cGAS-mediated ferroptosis and immune activation. In colorectal cancer models, cGAS signaling exerts tumor control via ATF3SLC7A11GPX4-mediated ferroptosis and IFNCD8 T cell-mediated antitumor immune response. | ||||
Zalcitabine
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [2] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Unspecific Target | ||||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
Capan-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0026 | ||
In Vivo Model |
NOD SCID mice (394) were purchased from Charles River Laboratories. Indicated wild-type or gene knockdown PANC1 cells (5 x 106 cells) were subcutaneously injected into the dorsal side of NOD SCID mice. At day 7, these mice were administrated with the indicated drug (zalcitabine [50 mg/kg, per day by i.p.], H-151 [750 nM per mouse, once every other day by i.p.], chloroquine [50 mg/kg, once every other day by i.p.], or liproxstatin-1 [10 mg/kg, once every other day by i.p.]) for 2 weeks.
Click to Show/Hide
|
||||
Response regulation | The antiviral drug zalcitabine can suppress pancreatic cancer cell growth through the induction of autophagy-dependent ferroptotic deathin vitroandin vivo. Mechanistically, these effects are dependent on mtDNA stress-induced activation of the CGAS-STING1 pathway. | ||||
References